EIP And Diffusion Combine To Form CNS Firm With Dementia Focus
Neflamapimod At Heart Of All-Stock Merger
The US biotechs are joining forces to form a new, listed company with sufficient cash to advance EIP’s potentially disease-modifying drug candidate through Phase II development in dementia with Lewy bodies, which presents a high unmet need.
You may also be interested in...
Agreement with Alexion is JCR’s first international deal for its blood-brain barrier drug delivery technology. Sartoris buys PolyPlus from private equity investors.
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.